Competition & Markets Authority
Illumina/PacBio abandon merger
Illumina has abandoned its anticipated $1.2 billion takeover of PacBio after an in-depth CMA merger probe highlighted serious competition concerns.
The Competition and Markets Authority (CMA) has therefore today confirmed that it will be cancelling its Phase 2 merger investigation.
Illumina, Inc. (Illumina) and Pacific Biosciences of California, Inc (PacBio) are both global suppliers of Next-Generation DNA sequencing systems to organisations across the world, including UK universities, laboratories and research institutes. DNA sequencing systems are vital to the study of genetic variation in humans and other species, for purposes such as essential disease research and drug development.
The CMA launched a Phase 2 inquiry in July 2019 after initial competition concerns led to the proposed merger being referred to a group of independent CMA panel members for an in-depth investigation.
The CMA provisionally found in October 2019 that the merger would result in a significant loss of competition between the 2 companies, with few alternative providers of DNA sequencing systems remaining. The CMA was also concerned that the loss of PacBio as an independent competitor would lead to a reduction in overall levels of innovation in the market. The CMA had proposed that blocking the merger would be the only way of addressing these concerns.
The deal was also being investigated by the US Federal Trade Commission, and the 2 authorities have cooperated closely throughout their respective investigations.
Illumina and PacBio have now decided not to continue with the deal. More information is available on the Illumina / PacBio case page.
Latest News from
Competition & Markets Authority
Private healthcare provider fixed prices with consultants25/09/2020 12:20:00
Lessons from the CMA’s investigation into Spire Healthcare's illegal agreement to fix the price of initial consultations for private self-pay patients.
CMA acts to protect competition on UK-US airline routes18/09/2020 09:20:00
Due to coronavirus, the CMA has imposed measures to protect competition on UK-US air routes while it investigates an agreement involving BA and American Airlines.
Motorcycle insurance broker merger raises competition concerns17/09/2020 09:20:00
The CMA has found that Ardonagh’s completed purchase of Bennetts could lead to higher prices, less choice and worse services for motorcyclists in the UK.
TUI UK to complete refunds by the end of the month16/09/2020 12:25:00
TUI UK has committed to the CMA that customers awaiting their refunds for holidays that were cancelled due to coronavirus will receive them by the end of the month.
Final decision published in window blind merger inquiry15/09/2020 09:20:00
The CMA has decided that Hunter Douglas, owner of online blinds retailer Blinds2Go, must sell the majority of its shares in 247 to protect competition and prevent higher prices.
Digital advertising merger to be abandoned during CMA investigation14/09/2020 13:25:00
Taboola has announced that it is to abandon its proposed purchase of Outbrain.
CMA updates competition law risk guide for managers11/09/2020 09:20:00
An updated guide to competition rules has been issued to help managers, directors and their advisers to stay on the right side of the law.
CMA to assess progress in legal services sector10/09/2020 09:20:00
The CMA is reviewing the legal services sector in England and Wales to assess whether transparency of price, quality and service have improved.